National Institute on Drug Abuse; Notice of Closed Meetings, 81922-81923 [2024-23322]
Download as PDF
<![CDATA[
81922
Federal Register / Vol. 89, No. 196 / Wednesday, October 9, 2024 / Notices
FR 46143–44). The estimated burden
total is slightly higher in this revised
notice because it incorporates estimates
for an MMHSUD program that was
funded following submission of the
previous notice.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Total
responses
Average
burden per
response
(in hours)
Total
burden
hours
HP Survey ............................................................................
Practice-Level Survey ..........................................................
Program Implementation Survey .........................................
Behavioral Health Consultation Provider SSI ......................
Care Coordinator SSI ..........................................................
Champion SSI ......................................................................
Community-Based and Other Resources SSI .....................
Program Implementation SSI ...............................................
23,256
6,172
67
67
67
67
50
134
1
1
1
1
1
1
1
1
23,256
6,172
67
67
67
67
50
134
0.33
0.33
0.33
0.75
0.75
0.50
0.50
1.00
7,674.48
2,036.76
22.11
50.25
50.25
33.50
25.00
134.00
Total ..............................................................................
29,880
........................
29,880
........................
10,026.35
Amy P. McNulty,
Deputy Director, Executive Secretariat.
[FR Doc. 2024–23293 Filed 10–8–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
responses per
respondent
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
SCORCH (Single Cell Opioid Responses in
the Context of HIV) Program: Data
Coordination, Analysis, and Scientific
Outreach; Data Mining and Functional
Validation.
Date: November 15, 2024.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
VerDate Sep<11>2014
17:05 Oct 08, 2024
Jkt 265001
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, caitlin.moyer@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Ending
the Epidemic: New Models of Integrated HIV/
AIDS, Addiction, and Primary Care Services.
Date: November 15, 2024.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Trinh T. Tran, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5843, trinh.tran@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIH
Support for Conferences and Scientific
Meetings.
Date: November 19, 2024.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Li Rebekah Feng, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–7245, rebekah.feng@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA).
Date: November 21, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Division of
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Extramural Review, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
Name of Committee: National Institute on
Drug Abuse, Special Emphasis Panel; NIDA
Avant-Garde Program for HIV and Substance
Use Disorder Research; NIDA Avenir Award
Program for HIV and Substance Use Disorder
Research.
Date: December 9, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Division of
Extramural Review, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Avant-Garde Program for HIV and Substance
Use Disorder Research; NIDA Avenir Award
Program for HIV and Substance Use Disorder
Research.
Date: December 12, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Division of
Extramural Review, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
E:\FR\FM\09OCN1.SGM
09OCN1
Federal Register / Vol. 89, No. 196 / Wednesday, October 9, 2024 / Notices
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: October 3, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2024–23322 Filed 10–8–24; 8:45 am]
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID SBIR Phase II
Clinical Trial Implementation Cooperative
Agreement (U44 Clinical Trial Required).
Date: November 7, 2024.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G41,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Tara Capece, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G41, Rockville, MD
20892, 240–191–4281, capecet2@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 3, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–23323 Filed 10–8–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:05 Oct 08, 2024
Jkt 265001
Center for Scientific Review; Notice of
Closed Meetings
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Fellowship:
NIH Medical Scientist Partnership Program
(FM1).
Date: October 31-November 1, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Raj K Krishnaraju, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6190,
MSC 7804, Bethesda, MD 20892, (301) 435–
1047, kkrishna@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Special
Topics in Clinical Neuroscience.
Date: November 4, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Boris P Sokolov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217A,
MSC 7846, Bethesda, MD 20892, 301–408–
9115, bsokolov@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 23–
077: Collaborative Program Grant for
Multidisciplinary Teams (RM1).
Date: November 4, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158,
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
81923
MSC 7806, Bethesda, MD 20892, 301–435–
1180, ruvinser@csr.nih.gov.
Name of Committee: Applied Immunology
and Disease Control Integrated Review
Group; Drug Discovery and Molecular
Pharmacology A Study Section.
Date: November 5–6, 2024.
Time: 8:30 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: DoubleTree by Hilton McLean
Tysons, 1960 Chain Bridge Rd., McLean, VA
22102.
Contact Person: Bidyottam Mittra, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, Bethesda, MD 20892, (301) 435–0000,
bidyottam.mittra@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Cell Biology, Developmental
Biology, and Bioengineering.
Date: November 5–6, 2024.
Time: 9:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alexander Gubin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4196,
MSC 7812, Bethesda, MD 20892, 301–435–
2902, gubina@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Infectious
Disease Drug Development and Molecular
Pharmacology.
Date: November 5–6, 2024.
Time: 10:00 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ekaterina Mikhailovna
Nestorovich, Scientific Review Officer, The
Center for Scientific Review, The National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 827–1367,
ekaterina.nestorovich@nih.gov.
Name of Committee: Applied Immunology
and Disease Control Integrated Review
Group; Anti-Infective Resistance and Targets
Study Section.
Date: November 6–7, 2024.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: Embassy Suites Alexandria Old
Town, 1900 Diagonal Road, Alexandria, VA
22314.
Contact Person: Jui Pandhare, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–7735, pandharej2@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neuroimmune and Neuroinflammation
involved in Neurodegenerative Disorders.
Date: November 6–7, 2024.
Time: 8:00 a.m. to 6:30 p.m.
E:\FR\FM\09OCN1.SGM
09OCN1
]]>Agencies
[Federal Register Volume 89, Number 196 (Wednesday, October 9, 2024)]
[Notices]
[Pages 81922-81923]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-23322]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; SCORCH (Single Cell Opioid Responses in the Context
of HIV) Program: Data Coordination, Analysis, and Scientific
Outreach; Data Mining and Functional Validation.
Date: November 15, 2024.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Caitlin Elizabeth Angela Moyer, Ph.D.,
Scientific Review Officer, Scientific Review Branch, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443-4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Ending the Epidemic: New Models of Integrated HIV/
AIDS, Addiction, and Primary Care Services.
Date: November 15, 2024.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 827-5843, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIH Support for Conferences and Scientific Meetings.
Date: November 19, 2024.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Li Rebekah Feng, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 827-7245, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA).
Date: November 21, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Division of Extramural Review, Scientific Review Branch,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 496-9350,
[email protected].
Name of Committee: National Institute on Drug Abuse, Special
Emphasis Panel; NIDA Avant-Garde Program for HIV and Substance Use
Disorder Research; NIDA Avenir Award Program for HIV and Substance
Use Disorder Research.
Date: December 9, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Division of Extramural Review, Scientific Review Branch,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 496-9350,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Avant-Garde Program for HIV and Substance Use
Disorder Research; NIDA Avenir Award Program for HIV and Substance
Use Disorder Research.
Date: December 12, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institutes of Health, National Institute on
Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Division of Extramural Review, Scientific Review Branch,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 496-9350,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research
[[Page 81923]]
Training; 93.279, Drug Abuse and Addiction Research Programs,
National Institutes of Health, HHS)
Dated: October 3, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-23322 Filed 10-8-24; 8:45 am]
BILLING CODE 4140-01-P
